NeoGenomics, Inc.
Financials
Valuation Metrics
NeoGenomics, Inc.'s Market Cap is $2.15B. At end of 2025 it was $303M. Ranked #1921 of 3,114 in US market (top 62%), #713 of 1,469 on NASDAQ (top 49%), #116 of 203 in Health Care Equipment & Services (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.15B | US#1,921/3,114 Sec#116/203 |
| Revenue | $788M | US#2,025/3,114 Sec#128/203 |
| Net Income | $-32M | US—/3,114 Sec—/203 |
| Total Assets | $1.38B | US#2,321/3,114 Sec#119/203 |
| Net Assets | $801M | US#1,927/3,114 Sec#103/203 |
| Employees | 2,500 | US#1,557/3,114 Sec#110/203 |
| Value | ||
| P/B | 2.68x | US#1,672/3,114 Sec#84/203 |
| P/S | 2.73x | US#1,617/3,114 Sec#111/203 |
| EV/EBITDA | 76.13x | US#2,465/3,114 Sec#139/203 |
| FCF Yield | -1.33% | US—/3,114 Sec—/203 |
| Profitability | ||
| ROE | -4.03% | US#2,297/3,114 Sec#126/203 |
| ROA | -2.35% | US#2,475/3,114 Sec#136/203 |
| Op. Margin | -5.98% | US#2,507/3,114 Sec#154/203 |
| Revenue Growth | 11.08% | US#1,147/3,114 Sec#79/203 |
| Financial Health | ||
| Debt Ratio | 71.98% | US#795/3,114 Sec#82/203 |
| Total Debt | $449M | US#1,922/3,114 Sec#102/203 |
| FCF | $-29M | US#2,362/3,114 Sec#150/203 |
| Cash | $139M | US#1,967/3,114 Sec#122/203 |
| Current Ratio | 3.53x | US#640/3,114 Sec#64/203 |
| Net Debt/EBITDA | 9.60x | US#2,479/3,114 Sec#141/203 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,114 Sec—/203 |
| Payout Ratio | 0.00% | US—/3,114 Sec—/203 |
| Performance | ||
| 1Y Return | 68.78% | US#369/3,114 Sec#37/203 |
| 1M Return | -10.72% | US#2,479/3,114 Sec#180/203 |
| From 52W High | -18.16% | US#1,382/3,114 Sec#108/203 |
| 1Y MDD | -40.54% | US#1,942/3,114 Sec#121/203 |
| Trading | ||
| Volume | 1,230,073 shares | US#877/3,114 Sec#36/203 |
| Trading Value | $21M | US#1,523/3,114 Sec#98/203 |
| Per Share | ||
| EPS | $-0.25 | US—/3,114 Sec—/203 |
| BPS | $6.15 | US#2,182/3,114 Sec#135/203 |
Company Info
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.